Almirall enters deal with Simcere on candidate ready for clinic

For a price that could exceed USD 500m, Chinese Simcere has signed away the global rights outside China to a potential treatment for a number of autoimmune disease.

Almirall could pay as much as USD 500m to develop and commercialize a drug hope from Simcere | Photo: Mikkel Aabenhus Hemmingsen / MedWatch

Spanish dermatology group Almirall has made an agreement with Chinese pharmaceutical firm Simcere regarding the rights to develop and commercialize drug candidate SIM0278 outside Greater China, including Hong Kong, Macau, and Taiwan, a press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs